

34. A composition as claimed in claim 32, comprising a Nef-Tat fusion protein or derivative thereof.

35. A composition according to claim 32, wherein the derivative of the Tat protein is a mutated Tat protein.

36. A composition according to claim 32, wherein the derivative of the Nef protein is a mutated Nef protein.

37. A composition as claimed in claim 32, wherein the fusion partner is a lipoprotein or derivative thereof.

38. A composition as claimed in claim 37, wherein the lipoprotein is Haemophilus Influenza B protein D or derivative thereof.

39. A composition as claimed in claim 38, wherein the fusion partner comprises between 100-130 amino acid from the N terminal of Haemophilus Influenza B protein D.

40. A composition as claimed in claim 32, wherein the Tat protein is the entire Tat protein.

41. A composition as claimed in claim 32, wherein the Nef protein is the entire Nef protein.

42. A composition as claimed in claim 32, wherein the Tat protein is fused to an HIV Nef protein and a fusion partner.

43. A composition as claimed in claim 32, wherein the protein has a Histidine tail.

44. A composition as claimed in claim 32, wherein the protein is carboxymethylated.

45. A composition as claimed in claim 32, additionally comprising an adjuvant.

46. A composition as claimed in claim 45, wherein the adjuvant is a TH1 inducing adjuvant.

00509260560

Sub. 32

MIT

Sub. D2

47. A composition as claimed in claim 45 which adjuvant comprises monophosphoryl lipid A or a derivative thereof such as 3 de-O-acylated monophosphoryl lipid A.
48. A composition as claimed in claim 45, additionally comprising a saponin adjuvant.
49. A composition as claimed in any one of claims 45 to 48 which additionally comprises an oil in water emulsion.
50. A composition as claimed in claim 32 further comprising HIV gp160 or its derivative gp120.
51. A composition as claimed in claim 45 further comprising HIV gp160 or its derivative gp120.
52. A composition as claimed in claim 48 further comprising HIV gp160 or its derivative gp120.
53. A composition as claimed in claim 49 further comprising HIV gp160 or its derivative gp120.
54. A protein comprising an HIV Tat protein or derivative thereof linked to an HIV Nef protein or derivative thereof in Nef-Tat or Tat-Nef orientation.
55. A nucleic acid encoding a protein of claim 54.
56. A host transformed with a nucleic acid of claim 55.
57. A host as claimed in claim 56 wherein the host is either *E. coli* or *Pichia pastoris*.
58. A method of producing a protein of claim 54, comprising providing a host as claimed in claim 56 or 57, expressing said protein and recovering the protein.

59. A method of preparing (i) an HIV Nef protein or derivative thereof or (ii) an HIV Tat protein or derivative thereof in *Pichia pastoris* which method comprises the steps of transforming *Pichia pastoris* with DNA encoding said HIV Nef protein or derivative thereof of HIV Tat protein or derivative thereof, expressing said protein and recovering the protein.
60. The method of claim 58 further comprising a carboxymethylation step performed on the expressed protein.
61. The method of claim 59 further comprising a carboxymethylation step performed on the expressed protein.
62. A method of producing a vaccine, comprising admixing the protein from claim 58 with a pharmaceutically acceptable diluent.
63. A method of producing a vaccine, comprising admixing the protein from claim 59 with a pharmaceutically acceptable diluent.
64. A method of producing a vaccine, comprising admixing the protein from claim 60 with a pharmaceutically acceptable diluent.
65. The method of claim 62 further comprising the addition of HIV gp160 or its derivative gp120.
66. The method of claim 63 further comprising the addition of HIV gp160 or its derivative gp120.
67. The method of claim 64 further comprising the addition of HIV gp160 or its derivative gp120.

0950923  
E260560

Handwritten signature/initials.

68. The method of claim 58 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
- 
69. The method of claim 59 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
70. The method of claim 60 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
71. The method of claim 61 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
72. The method of claim 62 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
73. The method of claim 63 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
74. The method of claim 64 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
75. The method of claim 65 further comprising the addition of an adjuvant, particularly a TH1 inducing adjuvant.
76. A vaccine composition comprising a recombinant Tat-containing protein formulated with a mixture of 3D-MPL, QS21 and an oil in water emulsion.
77. A composition as claimed in claim 76 wherein the oil in water emulsion comprises squalene, polyoxyethylene sorbitan monooleate and  $\alpha$ -tocopherol.
-